SOURCE: Golden Valley Development, Inc.

July 07, 2015 10:00 ET

Golden Valley Development, Inc. Announces the Enhancement of Its Management Team

FORT LAUDERDALE, FL--(Marketwired - Jul 7, 2015) - Golden Valley Development, Inc. (OTC PINK: GVDI) (the "Company"), a developer and marketer of patented and patentable technologies, is pleased to announce the appointments of Ms. Liliana Montes and Mr. Frank Melendez to the positions of Senior Vice Presidents of GVDI.

"The respective appointments of Liliana and Frank strengthen the already strong relationship between GVDI and Mel-Mont Medical," stated Kevin Sorrels, CEO of GVDI. "Liliana and Frank are dedicated to their mission to commercialize and establish as far reaching impact as possible for their life-saving medical technologies and products."

Ms. Montes, CEO of Mel-Mont Medical ("Mel-Mont") is an experienced operations and global logistics manager for the pharmaceutical/medical devices field, with vast experience in the regulatory and compliance field, especially Europe, Latin America and Middle East. She is also an authority in preventive cervical cancer sampling medical devices.

Mr. Melendez, COO of Mel-Mont Medical, LLC, is an experienced developer and inventor of medical devices and OTC formulations for the professional, retail, and medical product markets.

In their new positions with GVDI, Ms. Montes and Mr. Melendez will be placed in charge of the continued development and commercialization of XytoTest™, Mel-Mont's groundbreaking patentable self-sampling device that enables women anywhere in the world to either test themselves for the presence of cervical cancer or help them determine the likelihood they will develop this deadly cancer.

"We are delighted that GVDI has taken the important step to recruit both Frank and myself as Senior Vice Presidents of the Company. The partnership thus far fostered between GVDI and Mel-Mont is one of trust and mutual benefit. We thank the Company for placing the added trust in us to serve in the Company in these newly established senior positions, to further commercialize our product, and serve both GVDI and Mel-Mont's mission," stated Ms. Liliana Montes, CEO Mel-Mont Medical, SVP GVDI.

"The enhancement of GVDI's senior management team with the addition of Frank and Liliana is another important step forward in expanding the scope of our business, as well as creating as far reaching impact as possible. In the case of XytoTest™, we have an outstanding product that renders an outstanding life-saving service; we intend to continue the product's roll-out, whilst also developing new groundbreaking technologies," stated Kevin Sorrels, CEO of GVDI.

About Golden Valley Development, Inc
Golden Valley Development, Inc. ("GVDI" or "Company") is a holding company, developer, and marketer of patented and patentable technologies. As a holding company, GVDI is focused on technology and financial services, engaging in several business activities, the most significant being as a technology provider to third party logistic providers and as a financial service company for small-to-medium sized businesses (SMEs) worldwide.

About Mel-Mont Medical LLC
Mel-Mont Medical (MMM) researches, develops and markets comprehensive healthcare programs for the vulnerable and female population using proprietary medical devices. Founded in 2014, Mel-Mont Medical develops educational and self-sampling campaigns to reduce the spread of HPV infections. Also it provides information and education about Human Papilloma Virus (HPV) as a precursor of cervical cancer within the sexually active female population. Our health programs are directed to the vulnerable, female population located in rural areas of developing countries around the globe, where traditional health care systems are difficult and complex to implement. The company operates in the USA and emerging countries including Latin and South America with a focus in Colombia, where the company has offices, and Mexico.

For additional information contact Investor Relations at:

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's OTC Markets disclosures and filings ( The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

Contact Information